Emergent Biosolutions Inc (NYSE:EBS) Receives Consensus Rating of “Buy” from Brokerages

Emergent Biosolutions Inc (NYSE:EBS) has been given an average rating of “Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $70.33.

A number of equities research analysts have recently weighed in on the company. Cowen restated a “hold” rating and set a $60.00 price target on shares of Emergent Biosolutions in a research note on Friday, May 3rd. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, April 8th. Wells Fargo & Co set a $68.00 price target on Emergent Biosolutions and gave the stock a “hold” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price target on shares of Emergent Biosolutions in a research note on Sunday, April 21st. Finally, Chardan Capital set a $71.00 price target on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Friday, February 22nd.

In related news, Director Kathryn C. Zoon sold 1,376 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total value of $59,704.64. Following the sale, the director now owns 24,379 shares in the company, valued at $1,057,804.81. The sale was disclosed in a legal filing with the SEC, which is available through this link. 14.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in EBS. Rehmann Capital Advisory Group raised its stake in shares of Emergent Biosolutions by 78.7% in the fourth quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 199 shares during the last quarter. Semmax Financial Advisors Inc. bought a new position in shares of Emergent Biosolutions in the fourth quarter valued at approximately $30,000. Pearl River Capital LLC bought a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $34,000. Quantamental Technologies LLC raised its stake in shares of Emergent Biosolutions by 101.4% in the first quarter. Quantamental Technologies LLC now owns 999 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 503 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its stake in shares of Emergent Biosolutions by 1,108.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,112 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 1,020 shares during the last quarter. Institutional investors and hedge funds own 86.42% of the company’s stock.

Shares of Emergent Biosolutions stock opened at $43.36 on Monday. Emergent Biosolutions has a one year low of $39.64 and a one year high of $73.89. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 0.71 and a beta of 1.52. The company has a quick ratio of 1.28, a current ratio of 2.13 and a debt-to-equity ratio of 0.74.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.26). Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The business had revenue of $190.60 million for the quarter, compared to analysts’ expectations of $201.36 million. During the same quarter in the previous year, the firm posted ($0.03) EPS. Emergent Biosolutions’s revenue was up 61.8% on a year-over-year basis. On average, sell-side analysts anticipate that Emergent Biosolutions will post 3.06 EPS for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Further Reading: Yield Curve

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.